Axsome Therapeutics, Inc. (LON:0HKF)
London · Delayed Price · Currency is GBP · Price in USD | Market Cap | 8.37B +115.2% |
| Revenue (ttm) | 585.30M +56.9% |
| Net Income | -144.44M |
| EPS | -2.84 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 51 |
| Open | 220.00 |
| Previous Close | 221.52 |
| Day's Range | 215.22 - 220.00 |
| 52-Week Range | 104.72 - 263.93 |
| Beta | 0.73 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 10, 2026 |
About Axsome Therapeutics
Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company’s commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 ago... [Read more]
Financial Performance
In 2025, Axsome Therapeutics's revenue was $638.50 million, an increase of 65.55% compared to the previous year's $385.69 million. Losses were -$183.17 million, -36.22% less than in 2024.
Financial numbers in USD Financial StatementsNews
Axsome Therapeutics price target lowered to $297 from $304 at RBC Capital
RBC Capital analyst Leonid Timashev lowered the firm’s price target on Axsome Therapeutics (AXSM) to $297 from $304 and keeps an Outperform rating on the shares after the firm’s catch…
Axsome Therapeutics price target raised to $251 from $242 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Axsome Therapeutics (AXSM) to $251 from $242 and keeps an Equal Weight rating on the shares. The firm adjusted its estimates following…
Axsome Therapeutics price target raised to $275 from $260 at Guggenheim
Guggenheim raised the firm’s price target on Axsome Therapeutics (AXSM) to $275 from $260 and keeps a Buy rating on the shares, citing Axsome’s continued strong product performance, a growing…
Axsome Therapeutics price target raised to $256 from $255 at Wells Fargo
Wells Fargo raised the firm’s price target on Axsome Therapeutics (AXSM) to $256 from $255 and keeps an Overweight rating on the shares. The firm notes the uptake of Auvelity…
Axsome Therapeutics Earnings Call Transcript: Q2 2026
Q2 2026 saw 46% revenue growth to $218M, led by AUVELITY and SUNOSI, with AUVELITY's Alzheimer's agitation launch and sales force expansion accelerating demand. The neuroscience pipeline advanced, and cash reserves remain strong to support ongoing growth and R&D.
Axsome Therapeutics Earnings release: Q2 2026
Axsome Therapeutics released its Q2 2026 earnings on August 10, 2026, summarizing the period's financial results.
Axsome Therapeutics Slides: Q2 2026
Axsome Therapeutics has posted slides in relation to its Q2 2026 quarterly earnings report, which was published on August 10, 2026.
Axsome Therapeutics Quarterly report: Q2 2026
Axsome Therapeutics has published its Q2 2026 quarterly earnings report on August 10, 2026.
Axsome Therapeutics reports Q2 EPS (99c), consensus (85c)
Reports Q2 revenue $218.38M, consensus $221.78M. “The second quarter was highly productive for Axsome. Our commercial business grew robustly, driven by strong underlying demand for our products, and w...
Axsome Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update
Total 2Q 2026 net product revenue of $218.4 million, representing 46% year-over-year growth AUVELITY® 2Q 2026 net product sales of $180.3 million, representing 51% year-over-year growth SUNOSI® 2Q 202...
Axsome Therapeutics price target lowered to $306 from $310 at Mizuho
Mizuho lowered the firm’s price target on Axsome Therapeutics (AXSM) to $306 from $310 and keeps an Outperform rating on the shares.
Axsome Therapeutics initiated with an Outperform at BMO Capital
BMO Capital analyst Malcolm Hoffman initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price target The firm says the recent approval of Axsome’s Auvelity in Agitation...
Axsome Therapeutics initiated with an Outperform at BMO Capital
BMO Capital initiated coverage of Axsome Therapeutics (AXSM) with an Outperform rating and $310 price target
Axsome Therapeutics announces FDA acceptance of AXS-12 NDA
Axsome Therapeutics (AXSM) announced that the FDA has accepted for filing the company’s new drug application for AXS-12 for the treatment of cataplexy in narcolepsy. The FDA has set a…
Axsome Therapeutics Announces FDA Acceptance of New Drug Application for AXS-12 for the Treatment of Cataplexy in Narcolepsy
FDA sets PDUFA target action date of May 1, 2027 NEW YORK, July 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of...
Axsome Therapeutics to Report Second Quarter 2026 Financial Results on August 10
NEW YORK, July 14, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target raised to $304 from $302 at RBC Capital
RBC Capital analyst Leonid Timashev raised the firm’s price target on Axsome Therapeutics (AXSM) to $304 from $302 and keeps an Outperform rating on the shares as part of a…
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of Solriamfetol in Children with Attention Deficit Hyperactivity Disorder (ADHD)
The FOCUS-2 trial in children complements the recently announced FOCUS-3 trial in adolescents with ADHD NEW YORK, July 07, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharm...
Why Axsome Stock Has Doubled In Nine Months
In this week's edition of InnovationRx, we look at Axsome's growing pipeline, HistoSonics innovative cancer treatment, state litigation over Medicaid work requirements, and more. To get it in your inb...
Axsome Therapeutics doses first patient in FOCUS-3 trial
Axsome Therapeutics (AXSM) announced that the first patient has been dosed in the FOCUS-3 Phase 3 trial evaluating solriamfetol as a treatment for adolescents with attention deficit hyperactivity diso...
Axsome Therapeutics Initiates FOCUS-3 Phase 3 Trial of Solriamfetol in Adolescents with Attention Deficit Hyperactivity Disorder (ADHD)
NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Highlights the Importance of Brain Health During Alzheimer's & Brain Awareness Month
NEW YORK, June 18, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics price target raised to $300 from $275 at TD Cowen
TD Cowen analyst Joseph Thome raised the firm’s price target on Axsome Therapeutics (AXSM) to $300 from $275 and keeps a Buy rating on the shares. The firm said management…
Axsome Therapeutics Presents New Data Highlighting its Innovative Sleep Medicine Portfolio at SLEEP 2026
NEW YORK, June 15, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an...
Axsome Therapeutics Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
The session highlighted a strong CNS focus, rapid organizational growth, and a robust pipeline. AUVELITY's recent ADA approval and label advantages drove a peak sales guidance increase to $8 billion, supported by expanded sales force and payer coverage. Commercial and marketing strategies leverage synergies across indications.